VIROLOGICAL AND IMMMUNOLOGICAL STUDIES OF RECIPIENTS OF AN AIDS VACCINE

艾滋病疫苗(Microgenesys，GP 160)的第一阶段试验于#年开始 NIAID。疱疹病毒研究实验室正在进行 病毒学研究支持这一线索。巨细胞病毒培养 在接种疫苗之前和之后进行检查，以确定 预先存在的巨细胞病毒复制对疫苗的影响 响应性，反之，接种疫苗对 巨细胞病毒复制。启动了第二个gpl60型疫苗试验。 研究疫苗对无症状HIV抗体阳性的影响 个人。此外，EB病毒(EBV)的血清学研究， 从疫苗接种者的咽喉冲洗中分离EBV的尝试是 正在表演的。EBV已从9/25(36%)志愿者中分离到， 在13/35(37%)的血清中检测到EBV早期抗体 接种疫苗的人接受了测试。在正常健康的成年人中，EBV可以从 唾液中约有1%的血清呈阳性，早期抗体水平较低(较少 比1：20)的比例约为20%。早期抗体滴度大于 在这些志愿者中观察到的1：40通常出现在不到5%的 普通民众。因此，这些观察结果显示了一种反常的 在这些高危志愿者中，活动性EBV感染的高频率， 表明存在某种形式的免疫妥协 与艾滋病毒感染无关。这些志愿者的唾液样本也是 被收集用于检测HIV特异性唾液IgA抗体 可以在疫苗接受者身上得到证实。

Phase I trials of a vaccine for AIDS (Microgenesys, gp 160) were started at the NIAID. The Laboratory of Herpesvirus Research is performing virological studies in support of this trail. Cultures for cytomegalovirus' are being performed before and following vaccination to determine the influence of preexisting cytomegalovirus replication on vaccine responsiveness, and conversely, the influence of vaccination on the replication of cytomegalovirus. A second gpl6O vaccine trial was initiated to study the effects of the vaccine on asymptomatic HIV antibody positive individuals. In addition, serological studies of Epstein-Barr Virus (EBV), and attempts at the isolation of EBV from throat washes of vaccinees are being performed. EBV has been isolated from 9/25 (36%) volunteers, and early antibody to EBV has been detected in the sera of 13/35 (37%) vaccinees tested. In normal healthy adults, EBV can be isolated from the saliva of about 1% of seropositives, and early antibody at low levels (less than 1:20) can be found in about 20%. Early antibody at titers greater than 1:40, as observed in these volunteers, is usually found in less than 5% of the general population. Thus, these observations demonstrate an abnormally high frequency of active EBV infection in these high-risk volunteers, suggesting the existence of some form of immunological compromise independent of HIV infection. Saliva samples from these volunteers is also being collected for the measurement of HIV-specific salivary IgA antibodies can be demonstrated in vaccine recipients.